Author

I. A. Mellis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 3 Organism:virus· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Gordon· 5 shared D. D. Ho· 5 shared L. Liu· 5 shared Q. Wang· 5 shared R. Valdez· 5 shared Y. Guo· 4 shared C. Gherasim· 2 shared E. Stoneman· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Gordon

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Q. Wang, Y. Guo, L. T. Schwanz, I. A. Mellis, Y. Sun, Y. Qu, G. Urtecho, R. Valdez, E. Stoneman, A. Gordon, H. H. Wang, L. Liu, D. D. Ho

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

bioRxiv · Mar 10, 2024Microbiology

Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster

Q. Wang, I. A. Mellis, Y. Guo, C. Gherasim, R. Valdez, A. Gordon, L. Liu, D. D. Ho

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

bioRxiv · Feb 16, 2024 · PreprintImmunology

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants

Q. Wang, Y. Guo, A. Bowen, I. A. Mellis, R. Valdez, C. Gherasim, A. Gordon, L. Liu, D. D. Ho

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

bioRxiv · Nov 26, 2023 · PreprintImmunology

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

Q. Wang, Z. Li, Y. Guo, I. A. Mellis, S. Iketani, M. Liu, J. Yu, R. Valdez, A. S. Lauring, Z. Sheng, A. Gordon, L. Liu, D. D. Ho

The paper analyzes the receptor affinity and antibody evasion properties of SARS-CoV-2 BA.2.75 subvariants, identifying two evolutionary pathways and three mutations that influence their virological features.

bioRxiv · Mar 22, 2023Microbiology

SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster

Q. Wang, A. D. Bowen, A. R. Tam, R. Valdez, E. Stoneman, I. A. Mellis, A. Gordon, L. Liu, D. D. Ho

This study compares neutralizing antibody titers after bivalent and monovalent mRNA boosters and BA.5 breakthrough infection, finding no significant difference at one month but higher titers in breakthrough patients at three months.

bioRxiv · Feb 13, 2023 · PreprintMicrobiology

Genetic screening for single-cell variability modulators driving therapy resistance

E. A. Torre, E. Arai, S. Bayatpour, L. E. Beck, B. L. Emert, S. M. Shaffer, I. A. Mellis, M. Fane, G. Alicea, K. A. Budinich, A. Weeraratna, J. Shi, A. Raj

This study identifies genes that modulate cellular plasticity and influence therapy resistance in cancer cells through CRISPR screens, showing that manipulating plasticity before therapy can alter resistance.

bioRxiv · Nov 10, 2019Cell Biology